Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis

Angiogenesis

Volumn 3, Issue 3, 1999, Pages 259-269

  Zhou, Qing ^a   Nakada, Marian T ^b   Arnold, Catherine ^a   Shieh, Kate Y ^a   Markland Jr , Francis S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CENTOCOR INC   (United States)

Author keywords

Angiogenesis; Disintegrin; Integrin; Vitronectin receptor

Indexed keywords

AGKISTRODON; AGKISTRODON CONTORTRIX CONTORTRIX; MUS MUSCULUS; SERPENTES;

EID: 0001278780     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009059210733     Document Type: Article

References (50)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Folkman J. Editorial: Angiogenesis and breast cancer. J Clin Oncol 1994; 12: 441-3.
3. Folkman J. Tumor Angiogenesis. In: Holland JF, Bast RC, Morton DL, Frei III E, Kufe DW, Weichselbaum RR (eds) Cancer Medicine. Baltimore: Williams & Wilkins 1997; 181-204.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
5. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
6. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
7. Brooks PC, Montgomery AMP, Rosenfeld M et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
9. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
10. Stromblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996; 6: 462-8.
11. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 1995; 108: 2655-61.
12. Clark RAF, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of αvβ3 on vascular cells during wound repair. Am J Pathol 1996; 148: 1407-21.
13. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264: 569-71.
14. Stromblad S, Becker JC, Yebra B et al. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest 1996; 98: 426-33.
15. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-5.
16. El-Deiry WS, Harper JW, O'Connor PM et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74.
17. McLane M, Marcinkiewica C, Vijay-Kumar S et al. Viper venom disintegrins and related molecules [Review]. Proc Soc Exp Biol Med 1998; 219(2): 109-19.
18. Juliano D, Wang Y, Marcinkiewicz C et al. Disintegrin interaction with αvβ3 integrin on human umbilical vein endothelial cells: Expression of ligand-induced binding site on β3 subunit. Exp Cell Res 1996; 225: 132-42.
19. Sheu JR, Yen MH, Kan YC et al. Inhibition of angiogenesis in vitro and in vivo: Comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-αvβ3 integrin monoclonal antibody. Biochim Biophys Acta 1997; 1336: 445-54.
20. Yeh CH, Peng HC, Huang T-F. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin αvβ3 antagonist and inducing apoptosis. Blood 1998; 92(9): 3268-76.
21. Kang I-C, Lee Y-D, Kim D-S. A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res 1999; 59: 3754-60.
22. Trikha M, De Clerk YA, Markland FS. Contortrostatin, a snake venom disintegrin, inhibits β1 integrin-mediated human metastatic melanoma cell adhesion, and blocks experimental metastasis. Cancer Res 1994; 54: 4993-8.
23. Trikha M, Rote WE, Manley PJ et al. Purification and characterization of platelet aggregation inhibition from snake venoms. Thromb Res 1994; 73: 39-52.
24. Clark EA, Trikha M, Markland FS, Bruggs JS. Structurally distinct disintegrins contortrostatin and multisquamatin differentially regulate platelet tyrosine phosphorylation. J Biol Chem 1994; 269(35): 21940-3.
25. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717-21.
26. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45: 584-90.
27. Gasparini G, Harris AL. Prognostic significance of tumor vascularity. In Teicher BA (ed): Antiangiogenic Agents in Cancer Therapy. Totowa: Humana Press 1999; 317-39.
28. Repesh LA. A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 1989; 9: 192-208.
29. Brooks PC, Montgomery AMP, Cheresh DA. Use of the 10-day-old chick embryo model for studying angiogenesis. In Hewlett AR (ed): Methods in Molecular Biology. Totowa: Humana Press 1999; 257-69.
30. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear fragmentation. J Cell Biol 1992; 119: 493-501.
31. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4: 953-61.
32. Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
33. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
34. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993; 5: 864-8.
35. Wayner EA, Orlando RA, Cheresh DA. Integrins αvβ3 and αvβ5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol 1991; 113: 919-29.
36. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibroinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
37. Phillips DR, Charo IF, Scarborough RM. GP IIb-IIIa: The responsive integrin. Cell 1991; 65: 359-62.
38. Charo IF, Bekeart LS, Phillips DR. Platelet glycoprotein IIb-IIIa like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J Biol Chem 1987; 262: 9935-8.
39. Peerschke EI, Coller BS. A murine monoclonal antibody that blocks fibrinogen binding to normal platelets also inhibits fibrinogen interactions with chymotrypsin-treated platelets. Blood 1984; 64: 59-63.
40. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-29.
41. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996; 2: 167-8.
42. Brooks PC, Stromblad S, Klemke R et al. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
43. Luscinskas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEB J 1994; 930: 929-38.
44. Hynes RO. Integrins: Versatility modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
45. Clyman RI, Mauray F, Kramer RH. β1 and β3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp Cell Res 1992; 200: 272-84.
46. Jacob K, Bosserhoff AK, Wach F et al. Characterization of selected strongly and weakly invasive sublines of a primary human melanoma cell line and isolation of subtractive cDNA clones. Int J Cancer 1995; 60: 668-75.
47. Kawahara E, Imai K, Kumagai S et al. Inhibitory effects of adhesion oligopeptides on the invasion of squamous carcinoma cells with special reference to implication of αv integrins. J Cancer Res Clin Oncol 1995; 121: 133-40.
48. Liapis H, Adler LM, Wick MR, Rader JS. Expression of αvβ3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Human Pathol 1997; 28: 443-9.
49. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998; 140(5): 1255-63.
50. Klemke RL, Cai S, Giannini AL et al. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997; 137(2): 481-92.